Merck’s ENFLONSIA Receives ACIP Recommendation for Protecting Infants from Severe RSV
The Pharma Data
JUNE 26, 2025
CDC panel backs long-acting monoclonal antibody to protect infants during their first RSV season; drug also included in federal Vaccines for Children program Merck , operating as MSD outside the United States and Canada, has announced a key regulatory milestone for its respiratory syncytial virus (RSV) prevention program. What Is ENFLONSIA™?
Let's personalize your content